{
  "id": 14134598,
  "title": "Syndax Reports Phase 2 Setback For Axatilimab In Idiopathic Pulmonary Fibrosis",
  "url": "https://urgent.news/2026/10/13/syndax-reports-phase-2-setback-for-axatilimab-in-idiopathic-pulmonary",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-13T05:32:55.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/syndax-reports-phase-2-setback-axatilimab-idiopathic-pulmonary-fibrosis"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Syndax Pharmaceuticals Inc. (SNDX) announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualised rate of decline in forced vital capacity (FVC).",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}